In answer to the commentary about Hypos, in the FDAs analysis of the Hypo data during the (3rd) NDA process, there were a number of observations. The first interesting one from a T1 perspective is:
In active comparator studies where Afrezza TI was compared with another insulin, the incidence of hypoglycemia was generally lower for Afrezza TI than comparator, but in these studies the comparator groups had better glycemic efficacy than the Afrezza TI groups, confounding the hypoglycemia analyses.
If you read the protocols of these studies, Afrezza is used in an unusual way compared to the comparator, and it would not be used like this in the real world. For good reason too - the studies are designed to prove that Afrezza works as well as injected insulin in an unfavourable, but highly reproducible scenario. It's a shame that so few people have read the studies.
Looking closer at these studies, the results are truly amazing. Let's look at one of the FDA trials you referred to above, which was finally
published in December 2015:
The Afrezza group:
- Doses fixed for 7 days at a time
- Only flexibility allowed is a follow up blue (4u) at 90 minutes after eating
- Dose not allowed to be changed until the next week - even if known to be wrong
The Injected group:
- Dose adjustments/modifications were allowed at each meal for:
- carbohydrate counting
- meal size
- self-monitored blood glucose [SMBG] results
- snacks
- postprandial glucose [PPG] level
The Afrezza group had to use the
same dose for a no-carb meal with a starting glucose of 3.9 mmol/L as for a high-carb meal with a starting glucose of 12.0 mmol/L.
Amazingly, the Afrezza group still had far less hypoglycaemia - with almost the same HbA1c between the groups at the end of the trial (95%CI - 0.02–0.36%).
Even after correcting for the A1c level difference between the groups, Afrezza users had 43% lower rate of severe hypoglycaemic events (p=0.05) and 27% lower rate of total hypoglycaemia (p=0.0001).
These are stellar results, especially considering how users were instructed to use it. For a peek at how the results might look for an Afrezza trial without such unusual constraints, we can look closer at those who did best in both groups:
Comparing those that achieved A1C levels under 6.5% in both treatment groups, the injected insulin users had FIVE TIMES - 400% higher severe hypoglycaemia events per subject-month than the Afrezza users. They also had 20% less non-severe events too!
In patients whose A1c dropped by more than 0.6% by the end of the 6-month trial, the ones using Afrezza had about 40% less hypoglycaemic events per subject-month than the injected insulin users.
It's a shame they didn't use the GlycoMark 1,5AG test as well as HbA1c. The test reflects time spent over 10 mmol/L and doesn't reward hypoglycaemia.
Afrezza is amazing stuff. We have spent a fortune importing it and had great success with it. Unlike trial users, Matt checks his glucose before dosing Afrezza.